Fig. 1: Flow chart of study design.
From: Modifiable risk factors and plasma proteomics in relation to complications of type 2 diabetes
*After excluding individuals who refused to participant in follow-up (n = 127), and those free from type 2 diabetes at baseline (n = 478,142), 24,225 participants with type 2 diabetes were included. †A total sample of 14,102 type 2 diabetes patients with complete exposure data was used in the main analysis after exclusion of participants with missing information on modifiable risk factors (n = 10,123). LASSO, the least absolute shrinkage and selection operator.
